BR112018011331A2 - mutante de proteìna l1 de papillomavirus humano tipo 11 - Google Patents

mutante de proteìna l1 de papillomavirus humano tipo 11

Info

Publication number
BR112018011331A2
BR112018011331A2 BR112018011331-0A BR112018011331A BR112018011331A2 BR 112018011331 A2 BR112018011331 A2 BR 112018011331A2 BR 112018011331 A BR112018011331 A BR 112018011331A BR 112018011331 A2 BR112018011331 A2 BR 112018011331A2
Authority
BR
Brazil
Prior art keywords
protein
hpv
infection
types
human papillomavirus
Prior art date
Application number
BR112018011331-0A
Other languages
English (en)
Inventor
Li Shaowei
Wang Daning
Liu Xinlin
Li Zhihai
Zhang Jun
Xia Ningshao
Original Assignee
Xiamen Innovax Biotech Co., Ltd.
Xiamen University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xiamen Innovax Biotech Co., Ltd., Xiamen University filed Critical Xiamen Innovax Biotech Co., Ltd.
Publication of BR112018011331A2 publication Critical patent/BR112018011331A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

são divulgadas uma proteína l1 de hpv11 mutada (ou uma sua variante), uma sequência que codifica a mesma, um método para a preparação da mesma e uma partícula semelhante a vírus compreendendo a mesma, em que a proteína (ou uma sua variante) e a partícula semelhante pode induzir a geração de anticorpos neutralizantes contra pelo menos dois tipos de hpv (por exemplo, hpv11 e hpv6) e, portanto, pode ser usada para prevenir a infecção pelo pelo menos dois tipos de hpv e uma doença causada pela referida infecção, como câncer do colo do útero e condiloma acuminado. também divulga-se a utilização da proteína e da partícula semelhante a vírus na preparação de uma composição farmacêutica ou uma vacina para prevenir infecção pelos referidos pelo menos dois tipos de hpv e uma doen causada pela referida infecção, tal como câncer de cervical e condiloma acuminado
BR112018011331-0A 2015-12-04 2016-12-02 mutante de proteìna l1 de papillomavirus humano tipo 11 BR112018011331A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510887801 2015-12-04
CN201510887801.9 2015-12-04
PCT/CN2016/108349 WO2017092711A1 (zh) 2015-12-04 2016-12-02 一种人乳头瘤病毒11型l1蛋白的突变体

Publications (1)

Publication Number Publication Date
BR112018011331A2 true BR112018011331A2 (pt) 2019-04-30

Family

ID=58796324

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018011331-0A BR112018011331A2 (pt) 2015-12-04 2016-12-02 mutante de proteìna l1 de papillomavirus humano tipo 11

Country Status (7)

Country Link
US (1) US10513541B2 (pt)
EP (1) EP3385274B1 (pt)
JP (1) JP6920694B2 (pt)
KR (1) KR20180084139A (pt)
CN (1) CN106831958B (pt)
BR (1) BR112018011331A2 (pt)
WO (1) WO2017092711A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114127095B (zh) * 2019-07-19 2024-04-09 神州细胞工程有限公司 嵌合的人乳头瘤病毒11型l1蛋白
WO2021013067A1 (zh) * 2019-07-19 2021-01-28 神州细胞工程有限公司 嵌合的人乳头瘤病毒6型l1蛋白
EP4149536A1 (en) * 2020-05-14 2023-03-22 Inovio Pharmaceuticals, Inc. Vaccines for recurrent respiratory papillomatosis and methods of using the same
CN114539363B (zh) * 2020-11-26 2023-12-01 中国医学科学院基础医学研究所 一种c端改造的人乳头瘤病毒11型l1蛋白及其用途
KR20230126566A (ko) 2022-02-23 2023-08-30 충남대학교산학협력단 핵수송 신호 펩타이드가 접합된 핵산 전달용 2세대 폴리아미도아민 덴드리머 고분자 유도체
CN116041445B (zh) * 2023-01-06 2023-09-05 北京康乐卫士生物技术股份有限公司 一种人乳头瘤病毒51型l1蛋白突变体及减少重组蛋白降解的方法及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117591A0 (en) 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
US5795754A (en) 1995-07-19 1998-08-18 Merck & Co., Inc. Synthetic HPV11 virus-like particles
CA2237224C (en) * 1995-11-15 2006-06-27 Steven Ludmerer Synthetic hpv11 virus-like particles
US5738853A (en) * 1995-11-15 1998-04-14 Merck & Co., Inc. Synthetic HPV11 virus-like particles
AUPP765398A0 (en) 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
US6689366B1 (en) * 1998-12-17 2004-02-10 Merck & Co., Inc. Synthetic virus like particles with heterologous epitopes
DK2154149T3 (da) 2007-05-29 2019-10-14 Univ Xiamen En trunkeret l1-protein af human papillomavirus 6
DK2910566T5 (en) 2007-05-29 2016-11-07 Univ Xiamen Truncated L1 protein of human papillomavirus 11
CN101518647A (zh) * 2008-02-29 2009-09-02 江阴艾托金生物技术有限公司 人乳头瘤病毒预防性疫苗、构建方法及应用
JP5852883B2 (ja) * 2008-08-08 2016-02-03 タケダ ワクチン，インコーポレイテッド 交差反応性の増強のための複合カプシドアミノ酸配列を含むウイルス様粒子
CN102229660B (zh) * 2011-05-25 2015-04-22 厦门大学 截短的人乳头瘤病毒33型l1蛋白
CN102747047B (zh) * 2012-02-28 2016-03-23 厦门大学 人乳头瘤病毒型别杂合病毒样颗粒及其制备方法
CN104211782B (zh) * 2013-06-04 2017-11-17 厦门大学 截短的人乳头瘤病毒45型l1蛋白

Also Published As

Publication number Publication date
EP3385274A4 (en) 2019-08-14
JP6920694B2 (ja) 2021-08-18
CN106831958A (zh) 2017-06-13
JP2019502404A (ja) 2019-01-31
US20190062379A1 (en) 2019-02-28
EP3385274B1 (en) 2021-09-22
US10513541B2 (en) 2019-12-24
WO2017092711A1 (zh) 2017-06-08
CN106831958B (zh) 2020-12-29
KR20180084139A (ko) 2018-07-24
EP3385274A1 (en) 2018-10-10

Similar Documents

Publication Publication Date Title
BR112018011331A2 (pt) mutante de proteìna l1 de papillomavirus humano tipo 11
BR112018011310A2 (pt) mutante da proteína l1 do papilomavírus humano tipo 58
BR112013030150A2 (pt) proteína l1 hpv33 truncada ou variante da mesma, ácido nucléico isolado, vetor, célula hospedeira, partícula do tipo viral hpv33, composição, composição farmacêutica ou vacina, método para obter uma proteína l1 hpv33 truncada, método para preparar a partícula do tipo viral hpv33, método para preparar uma vacina, método para prevenir a infecção hpv ou uma doença causada pela infecção de hpv e uso da proteína l1 hpv33 truncada ou variante da mesma
BR112019000598A2 (pt) rna para terapia de câncer
BR112012022669A2 (pt) composição imunogênica, método de tratamento ou prevenção de infecção ou doença, uso de um antígeno, kit, métodos para a fabricação de uma composição imunogênica e para melhorar uma vacina.
BR112017018368A2 (pt) composições contendo rna para o tratamento de doenças tumorais
BR112015022096A8 (pt) compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos
TR201908199T4 (tr) HPV'ye karşı aşılar.
CO6480995A2 (es) Construcciones novedosas de proteina del virus de pailoma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv
BR112017005111A2 (pt) compostos, composição farmacêutica, usos de um composto ou de um sal farmaceuticamente aceitável do mesmo para o tratamento de um hospedeiro infectado com um papilomavírus humano, usos de um composto, método para a fabricação de um medicamento destinado ao uso terapêutico para o tratamento de uma infecção por papilomavírus
MX2020011299A (es) Vacunas mejoradas para el virus del papiloma humano y metodos para utilizarlas.
MX2017007178A (es) Formulaciones liquidas estables de virus de vacuna.
BR112013005427A2 (pt) composição imunogênica, vacina, método para tratamento ou prevenção de doença, e para preparar a composição imunogênica ou vacina, uso da vacina,e, composição farmacêutica.
BR112016015422A2 (pt) formulações de vacina de frasco único
IN2014DN03054A (pt)
BRPI0810959A2 (pt) "proteína l1 do hpv11, polinucleotídeo, vetor, célula, composição, partícular semelhante ao vírus (vlp) hp11, método para produzir uma proteína l1 do hpv,vacina para prevenção de condiloma acuminado ou de infecções por hpv, uso da proteína método para prevenção de condiloma acuminado ou infecções por hpv e método para prevenção de condiloma acuminado ou infecções por hpv.
AR108829A1 (es) Vacuna contra virus de bronquitis infecciosa
HRP20211749T1 (hr) Pentanske kiseline supstituirane pirolo-[2-3,b]pirimidin-piridinima za liječenje virusnih infekcija influencom
BR112013029417A2 (pt) composições de vacina de matriz proteica incluindo policátions
EP2589604A4 (en) SHORTEN L1 PROTEIN OF THE TYPE 52 HUMAN PAPILLOMA VIRUS
GT201000066A (es) Una vacuna multicomponente o monocomponente, para ser utilizada contra la enfermedad de chagas, composiciones farmaceuticas que las contienen, procedimiento para la obtención del inmunógeno de dichas vacunas y acido nucleico utilizado en dicho proced
BR112016025977A2 (pt) composições, métodos e utilizações para formulações de papilomavirus humano estábulo estável
AR054259A1 (es) Vacuna contra virus de papiloma humano (hpv)
BR112013001946A2 (pt) vírus varicela zoster inativado, composição farmacêutica, método para preparar um vírus varicela zoster inativado, vacina, e, método para o tratamento de herpes zoster em um indivíduo
CO6341567A2 (es) Vacuna contra el virus de papiloma humano

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]